Get all your news in one place.
100's of premium titles.
One app.
Start reading
Bangkok Post
Bangkok Post
National
ONLINE REPORTERS

WHO certifies Thai anti-HIV drug

Dr Sopon Mekthon, chairman of the Government Pharmaceutical Organization, centre, and GPO deputy managing director Mukdavan Prakobvaitayakit, left, announce the WHO has certified the GPO's anti-HIV medication Efavirenz, at the GPO plant in Thanyaburi district of Pathum Thani on Friday. (Photos by Tawatchai Kemgumnerd)

The World Health Organization has certified the Government Pharmaceutical Organization's antiretroviral drug Efavirenz, and the GPO is now looking to overseas sales.

GPO chairman Sopon Mekthon said on Friday that Efavirenz is the first drug developed in Thailand and Asean to pass the WHO Prequalification Programme and be included in the WHO's prequalified list.

Consequently, international health organisations such as the Global Fund and Unicef can order the medication for use in underdeveloped countries, he said.

The WHO certified it in August.

Efavirenz is the medication prescribed to all HIV-infected people when they are first diagnosed with the virus, Dr Sopon said.

Mukdavan Prakobvaitayakit, deputy managing director of the GPO, said the organisation had taken 16 years to develop the drug, which has the same properties as the prototype medication. The antiretroviral agent had passed the WHO's meticulous examination.

The locally made product is marketed at 180 baht per bottle of 30 600mg tablets, while the imported product retailes at more than 1,000 baht per bottle, she said.

After the WHO's certification, many countries asked the GPO to register the medication there so they could order it, Ms Mukdavan said.

She cited the Philippines and Caribbean countries as examples. The Philippines planned to order about 300,000 bottles at a cost of 51 million baht, she said.

The GPO would produce 42 million Efavirenz tablets this year. This amount accounted for only 2.5% of the total capacity of the GPO, she said.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.